Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients

被引：13
|
作者：
Frank, U [1 ]
Mutter, J [1 ]
Schmidt-Eisenlohr, E [1 ]
Daschner, FD [1 ]
机构：
[1] Freiburg Univ Hosp, Inst Environm Med & Hosp Epidemiol, D-79106 Freiburg, Germany
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2003年 / 9卷 / 11期
关键词：
beta-lactamase-inihibitor; susceptibility testing; nosocomial pathogens;
D O I：
10.1046/j.1469-0691.2003.00786.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We investigated the antimicrobial activity of piperacillin-tazobactam versus piperacillin-sulbactam against common nosocomial pathogens (n = 565) isolated from intensive care patients. For Gram-positive bacteria, antimicrobial susceptibilities to the two piperacillin-beta-lactamase inhibitor combinations were almost identical. For Gram-negative bacteria, piperacillin-tazobactam exhibited greater activity against Escherichia coli and Proteus vulgaris than piperacillin-sulbactam. Both combinations, however, were equally effective against the other Enterobacteriaceae and Pseudomonas aeruginosa isolates. Piperacillin-sulbactam exhibited better antimicrobial activity against Acinetobacter baumannii. Our findings might prove important for the appropriate choice of antibiotic therapy with beta-lactam-beta-lactamase inhibitor combinations.
引用
收藏
页码：1128 / 1132
页数：5
相关论文
共 50 条
  • [1] Piperacillin-sulbactam versus piperacillin-tazobactam:: a multicentre, randomised, single-blind, controlled clinical trial
    Zong, ZY
    Lü, XJ
    Liu, YB
    Yao, Y
    Yu, RJ
    Fu, XQ
    Huang, WX
    Cai, SF
    Yu, ZB
    Zeng, XP
    Duan, MG
    Xia, PY
    Zhu, WM
    Ji, XH
    Zhao, HW
    Chen, YC
    Fei, Y
    Ni, ZZ
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (01) : 22 - 27
  • [2] Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: Studies with piperacillin-tazobactam and piperacillin-sulbactam
    Lister, PD
    Prevan, AM
    Sanders, CC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 721 - 727
  • [3] In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis
    Weber, Andreas
    Huber, Wolfgang
    Kamereck, Klaus
    Winkle, Philipp
    Voland, Petra
    Weidenbach, Hans
    Schmid, Roland M.
    Prinz, Christian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (20) : 3174 - 3178
  • [4] In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis
    Andreas Weber
    Wolfgang Huber
    Klaus Kamereck
    Philipp Winkle
    Petra Voland
    Hans Weidenbach
    Roland M Schmid
    Christian Prinz
    World Journal of Gastroenterology, 2008, (20) : 3174 - 3178
  • [5] In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units
    Bonfiglio, G
    Laksai, Y
    Franceschini, N
    Perilli, M
    Segatore, B
    Bianchi, C
    Stefani, S
    Amicosante, G
    Nicoletti, G
    CHEMOTHERAPY, 1998, 44 (05) : 305 - 312
  • [6] Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
    Ibrahim El-Haffaf
    Jean-Alexandre Caissy
    Amélie Marsot
    Clinical Pharmacokinetics, 2021, 60 : 855 - 875
  • [7] Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
    El-Haffaf, Ibrahim
    Caissy, Jean-Alexandre
    Marsot, Amelie
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 855 - 875
  • [8] Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis
    Mueller, SC
    Majcher-Peszynska, J
    Hickstein, H
    Francke, A
    Pertschy, A
    Schulz, M
    Mundkowski, R
    Drewelow, B
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) : 1557 - 1560
  • [9] Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients
    Verbist, L
    Verhaegen, J
    Wouters, C
    Vandenhoven, G
    Allemeersch, D
    Bardiau, C
    Bellon, A
    Carpentier, M
    Colaert, J
    Crokaert, F
    DHont, N
    DeBrauw, W
    Deckers, P
    Declercq, P
    Dediste, A
    Delmee, M
    DeMol, P
    deMuelenaere, G
    DePuydt, H
    Desmarets, JM
    DeWeer, M
    Dierick, J
    Fameree, D
    Garrino, MG
    Glupczynski, I
    Goffinet, P
    Gonissen, V
    Goossens, H
    Hemmer, R
    Hubrechts, JM
    Leclercq, M
    Lievens, P
    Maes, P
    Magerman, K
    Marchal, JF
    Martens, F
    Melin, P
    Mertens, HJ
    Mertens, A
    Meunier, F
    Pauquay, F
    Pepersack, F
    Potvliege, C
    Schneider, F
    Simon, G
    Simon, A
    Smekens, J
    Trigoux, J
    Ursi, JP
    Vael, C
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (02) : 285 - 293
  • [10] Comparative in vitro activity of piperacillin/tazobactam against Gram-negative bacilli
    Liebowitz, LD
    Klugman, KP
    SOUTH AFRICAN MEDICAL JOURNAL, 1996, 86 (10): : 1276 - 1280
12345